179 related articles for article (PubMed ID: 17285455)
1. American Society of Hematology--48th Annual Meeting and Exposition. Treatments for leukemia and lymphoma. 9-12 December 2006 Orlando, FL, USA.
Talmadge JE
IDrugs; 2007 Feb; 10(2):87-9. PubMed ID: 17285455
[No Abstract] [Full Text] [Related]
2. American Society of Hematology--48th Annual Meeting and Exposition. Updates on therapies. 9-12 December 2006 Orlando, FL, USA.
Clemetson KJ
IDrugs; 2007 Feb; 10(2):90-2. PubMed ID: 17285456
[No Abstract] [Full Text] [Related]
3. American Society of Hematology--48th Annual Meeting and Exposition. Therapeutic approaches for hematological cancers. 9-12 December 2006 Orlando, FL, USA.
Tear S
IDrugs; 2007 Feb; 10(2):84-6. PubMed ID: 17285454
[No Abstract] [Full Text] [Related]
4. American Society of Hematology--48th Annual Meeting and Exposition. 9-12 December 2006, Orlando, FL, USA.
Walker K
IDrugs; 2007 Feb; 10(2):75-7. PubMed ID: 17285451
[No Abstract] [Full Text] [Related]
5. American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.
Walker K
IDrugs; 2007 Feb; 10(2):78-80. PubMed ID: 17285452
[No Abstract] [Full Text] [Related]
6. American Society of Hematology--48th Annual Meeting and Exposition. The Factor Xa target, and disorders of platelet number and function. 9-12 December 2006 Orlando, FL, USA.
Tear S
IDrugs; 2007 Feb; 10(2):81-3. PubMed ID: 17285453
[No Abstract] [Full Text] [Related]
7. 49th Annual Meeting of the American Society of Hematology, Atlanta, GA; December 8-11, 2007.
Clin Lymphoma Myeloma; 2008 Apr; 8(2):77-86. PubMed ID: 18564453
[No Abstract] [Full Text] [Related]
8. Advances in the treatment of T-cell lymphoma. A review of presentations from the 48th annual meeting of the American Society of Hematology, December 9-12, 2006, Orlando, Florida, USA.
Clin Adv Hematol Oncol; 2007 Oct; 5(10 Suppl 16):1-10; quiz 11-12. PubMed ID: 18185490
[No Abstract] [Full Text] [Related]
9. American Society of Hematology--50th Annual Meeting and Exposition--Part 2.
Cleverley J; Millar E
IDrugs; 2009 Feb; 12(2):66-8. PubMed ID: 19216125
[No Abstract] [Full Text] [Related]
10. Highlights in leukemia and lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition.
Clin Adv Hematol Oncol; 2021 Mar; 19 Suppl 11(3):1-20. PubMed ID: 33843915
[No Abstract] [Full Text] [Related]
11. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.
Pidala J; Kim J; Alsina M; Ayala E; Betts BC; Fernandez HF; Field T; Jim H; Kharfan-Dabaja MA; Locke FL; Mishra A; Nishihori T; Ochoa-Bayona L; Perez L; Riches M; Anasetti C
Haematologica; 2015 Jul; 100(7):970-7. PubMed ID: 25840599
[TBL] [Abstract][Full Text] [Related]
12. Highlights in leukemia and lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary.
Barr PM
Clin Adv Hematol Oncol; 2021 Mar; 19 Suppl 11(3):17-19. PubMed ID: 33843916
[No Abstract] [Full Text] [Related]
13. Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma.
Grigg A; Bardy P; Byron K; Seymour JF; Szer J
Bone Marrow Transplant; 1999 Jan; 23(2):107-10. PubMed ID: 10197793
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience.
Nelson R; Shapiro JF; Perkins JB; Kim J; Nishihori T; Pidala J; Ayala E; Locke FL; Field T; Mishra A; Riches M; Betts B; Perez L; Yue B; Ochoa-Bayona JL; Alsina M; Fernandez H; Anasetti C; Kharfan-Dabaja MA
Bone Marrow Transplant; 2015 Nov; 50(11):1487-9. PubMed ID: 26301969
[No Abstract] [Full Text] [Related]
15. Leukemia and lymphoma.
White LP
Geriatrics; 1970 Dec; 25(12):82-6. PubMed ID: 5274229
[No Abstract] [Full Text] [Related]
16. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the treatment of leukemia, lymphoma, and myeloma. [Review of Selected Presentations From the 52nd American Society of Hematology Annual Meeting and Exposition. December 4–7, 2010. Orlando, Florida].
Cheson BD
Clin Adv Hematol Oncol; 2011 Apr; 9(4 Suppl 7):1-24. PubMed ID: 21558999
[No Abstract] [Full Text] [Related]
18. The American Society of Hematology--46th Annual Meeting and Exposition. Drug highlights I.
Evans L
IDrugs; 2005 Jan; 8(1):7-9. PubMed ID: 15650932
[No Abstract] [Full Text] [Related]
19. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus and mycophenolate mofetil combination.
Saini N; Nath R; Cerny J
Ann Hematol; 2017 Sep; 96(9):1563-1568. PubMed ID: 28710649
[No Abstract] [Full Text] [Related]
20. The American Society of Hematology--46th Annual Meeting and Exposition. Drug highlights II.
Evans L
IDrugs; 2005 Jan; 8(1):10-3. PubMed ID: 15650933
[No Abstract] [Full Text] [Related]
[Next] [New Search]
